This study was conducted in Baghdad, Iraq from December 2021 to May 2022. The goal was to determine the effect of Toxoplasma gondii on liver function by examining the relationship between Toxoplasma infection and hormones. One hundred and twenty male patients with Chronic liver disease (CLD) (age:14-75 years) and 120 control males (age: 24-70 years) participated in this study. Serum samples were taken from all individuals and were then analysed for anti-Toxoplasma antibodies. Hormonal tests were conducted for all participants which included (Cortisol, testosterone, prolactin, insulin, and thyroid-stimulating hormone TSH). Biochemical tests included (Prothrombin time PT, international normalized ratio INR and albumin); liver enzymes evaluated were (aspartate aminotransferase AST, alanine aminotransferase ALT, alkaline phosphatase ALP and gamma-glutamyl transferase GGT) and interleukins (Interleukin 13 IL-13 and transforming growth factor TGF). According to the anti-Toxoplasma antibodies results, 32 (26% of the control group) of the participants tested positive for anti-Toxoplasma antibodies, compared to 60 (50%) of the CLD patients. Four sub-groups were formed in response to prior results: Control-Toxoplasma positive, control-Toxoplasma negative, CLD-Toxoplasma positive and CLD-Toxoplasma negative. The seropositive status of T. gondii did not affect the following hormones: cortisol, testosterone,insulin and TSH while it was related significantly to prolactin. The results of liver enzymes showed that T. gondii positive status was significantly related to all enzymes among CLD patients except the GGT enzyme T. gondii positive status was not correlated with the other biochemical (PT, INR, and albumin) and immunological parameters (IL-13 and TGF).
